AC Immune (NASDAQ:ACIU) Announces Quarterly Earnings Results

AC Immune (NASDAQ:ACIU) announced its quarterly earnings results on Wednesday. The company reported ($0.16) EPS for the quarter, beating analysts’ consensus estimates of ($0.22) by $0.06, FiscalAI reports. AC Immune had a negative return on equity of 100.17% and a negative net margin of 245.32%. The firm had revenue of $3.88 million for the quarter, compared to analyst estimates of $0.33 million.

AC Immune Stock Up 7.5%

Shares of ACIU traded up $0.16 during mid-day trading on Wednesday, hitting $2.25. 168,935 shares of the company’s stock traded hands, compared to its average volume of 265,672. AC Immune has a 1 year low of $2.02 and a 1 year high of $3.90. The firm has a market capitalization of $228.58 million, a P/E ratio of -4.16 and a beta of 1.64. The business’s 50-day moving average price is $2.58 and its 200-day moving average price is $2.72.

Wall Street Analyst Weigh In

ACIU has been the subject of several recent research reports. Zacks Research cut AC Immune from a “strong-buy” rating to a “hold” rating in a research note on Wednesday, October 28th. HC Wainwright restated a “buy” rating on shares of AC Immune in a report on Thursday, September 24th. BTIG Research reissued a “buy” rating and issued a $8.00 price target on shares of AC Immune in a research report on Wednesday, September 23rd. Finally, Weiss Ratings lowered AC Immune from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Tuesday, October 20th. Three equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, AC Immune currently has an average rating of “Hold” and an average target price of $7.50.

About AC Immune

AC Immune SA is a clinical-stage biopharmaceutical company headquartered in Lausanne, Switzerland, focused on developing treatments and diagnostic products for neurodegenerative diseases. Its research primarily addresses Alzheimer’s disease, Parkinson’s disease and related disorders by targeting proteins believed to contribute to disease progression, including amyloid and tau.

The company’s technology platforms include SupraAntigen, which supports the discovery of antibodies and vaccines, and Morphomer, which is used to identify small-molecule compounds that may prevent or modify the abnormal aggregation of disease-associated proteins.